tiprankstipranks
Advertisement
Advertisement

VTGN Stock Latest News

VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
Company AnnouncementsVistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
7d ago
8K
VTGN
AbCellera target is profile more attractive than Vistagen, says JonesResearch
PremiumThe Fly
AbCellera target is profile more attractive than Vistagen, says JonesResearch
13d ago
ABCL
VTGN
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
PremiumThe Fly
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
13d ago
VTGN
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
PremiumCompany Announcements
VistaGen Therapeutics Grants Broad Employee Retention Stock Options
22d ago
8K
VTGN
VistaGen Faces Nasdaq Audit Committee Compliance Setback
PremiumCompany Announcements
VistaGen Faces Nasdaq Audit Committee Compliance Setback
1M ago
8K
VTGN
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation
PremiumCompany AnnouncementsVistaGen Showcases Intranasal Pherine Pipeline in New Presentation
2M ago
8K
VTGN
VistaGen Announces Workforce Reduction to Extend Cash Runway
Premium
Company Announcements
VistaGen Announces Workforce Reduction to Extend Cash Runway
2M ago
8K
VTGN
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
Premium
Class Action
VISTAGEN THERAPEUTICS CLASS ACTION: LEVI & KORSINSKY, LLP EXPLAINS LEAD PLAINTIFF DEADLINE AND PROCESS
2M ago
VTGN
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
PremiumMarket News
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
2M ago
VTGN
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
PremiumClass Action
LEVI & KORSINSKY, LLP: UNDERSTANDING THE LEGAL FRAMEWORK FOR THE VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
2M ago
VTGN
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
PremiumCompany Announcements
High-Risk Warning: Analyst Flags Significant Uncertainties for Vistagen Therapeutics Investors
3M ago
VTGN
Vistagen Therapeutics Balances Progress and Uncertainty
PremiumCompany Announcements
Vistagen Therapeutics Balances Progress and Uncertainty
3M ago
VTGN
Vistagen reports Q3 EPS (45c), consensus (49c)
PremiumThe FlyVistagen reports Q3 EPS (45c), consensus (49c)
3M ago
VTGN
VTGN Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
VTGN Earnings this Week: How Will it Perform?
3M ago
VTGN
VistaGen Receives Nasdaq Notice on Minimum Bid Compliance
Premium
Company Announcements
VistaGen Receives Nasdaq Notice on Minimum Bid Compliance
3M ago
8K
VTGN
Vistagen Therapeutics (VTGN) Faces Securities Litigation Following 80% Stock Collapse [January 2026]
PremiumClass Action
Vistagen Therapeutics (VTGN) Faces Securities Litigation Following 80% Stock Collapse [January 2026]
3M ago
VTGN
Vistagen Drug Trial Collapse Triggers Investor Lawsuit Wave
PremiumClass Action
Vistagen Drug Trial Collapse Triggers Investor Lawsuit Wave
4M ago
VTGN
VistaGen updates corporate presentation highlighting neuroscience pipeline
PremiumCompany Announcements
VistaGen updates corporate presentation highlighting neuroscience pipeline
4M ago
8K
VTGN
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
PremiumCompany Announcements
VistaGen’s PALISADE-3 Trial Fails Primary Endpoint in SAD
4M ago
8K
VTGN
Vistagen downgraded to Hold from Buy at Jefferies
PremiumThe FlyVistagen downgraded to Hold from Buy at Jefferies
5M ago
VTGN
Vistagen downgraded to Hold at Jefferies after social anxiety study miss
Premium
The Fly
Vistagen downgraded to Hold at Jefferies after social anxiety study miss
5M ago
VTGN
Vistagen downgraded to Hold from Buy at Maxim
Premium
The Fly
Vistagen downgraded to Hold from Buy at Maxim
5M ago
VTGN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >